Skip to Main Content

Paper Details

Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population.
Curr Med Res Opin
4
2022
AD, HOI, HOIs, JAK, JAK-, Janus Kinase, Janus kinase, RA, atopic dermatitis, baricitinib, chronic kidney disease, depression, hypertension, obesity, patient, patients, rheumatoid arthritis, tofacitinib, upadacitinib
Author NameAffiliation
Manisha DesaiStanford University School of Medicine
Manisha DesaiStanford University School of Medicine
  • 1 - 2

Datasets

Release 1.2